SG10201701101YA - Methods for improving diaphragm function - Google Patents
Methods for improving diaphragm functionInfo
- Publication number
- SG10201701101YA SG10201701101YA SG10201701101YA SG10201701101YA SG10201701101YA SG 10201701101Y A SG10201701101Y A SG 10201701101YA SG 10201701101Y A SG10201701101Y A SG 10201701101YA SG 10201701101Y A SG10201701101Y A SG 10201701101YA SG 10201701101Y A SG10201701101Y A SG 10201701101YA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- diaphragm function
- improving diaphragm
- improving
- function
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261619261P | 2012-04-02 | 2012-04-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201701101YA true SG10201701101YA (en) | 2017-04-27 |
Family
ID=49300969
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201701101YA SG10201701101YA (en) | 2012-04-02 | 2013-04-01 | Methods for improving diaphragm function |
SG11201406270YA SG11201406270YA (en) | 2012-04-02 | 2013-04-01 | Methods for improving diaphragm function |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201406270YA SG11201406270YA (en) | 2012-04-02 | 2013-04-01 | Methods for improving diaphragm function |
Country Status (15)
Country | Link |
---|---|
US (2) | US20150065525A1 (en) |
EP (1) | EP2834269A4 (en) |
JP (3) | JP6345645B2 (en) |
KR (1) | KR20160046693A (en) |
CN (2) | CN108553467A (en) |
AU (2) | AU2013243671B2 (en) |
BR (1) | BR112014024552A2 (en) |
CA (1) | CA2868507A1 (en) |
EA (1) | EA031183B1 (en) |
HK (1) | HK1206364A1 (en) |
IL (2) | IL234885A0 (en) |
MX (1) | MX354965B (en) |
PH (1) | PH12014502217A1 (en) |
SG (2) | SG10201701101YA (en) |
WO (1) | WO2013151938A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
AR081331A1 (en) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081626A1 (en) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS |
JP2014517079A (en) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Compounds useful as ATR kinase inhibitors |
CN109316480A (en) | 2011-07-13 | 2019-02-12 | 赛特凯恩蒂克公司 | Combine ALS therapy |
CN104395458A (en) * | 2012-04-11 | 2015-03-04 | 赛特凯恩蒂克公司 | Improving resistance to skeletal muscle fatigue |
ES2842876T3 (en) | 2012-12-07 | 2021-07-15 | Vertex Pharma | Pyrazolo [1,5-a] pyrimidines useful as ATR kinase inhibitors for the treatment of cancer diseases |
ES2665619T3 (en) | 2013-03-14 | 2018-04-26 | Novartis Ag | 3-Pyrimidin-4-yl-oxazolidin-2-ones as mutant HDI inhibitors |
JP2016512816A (en) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
JP2016512815A (en) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Condensed pyrazolopyrimidine derivatives useful as inhibitors of ATR kinase |
EP2970289A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
DK3077397T3 (en) | 2013-12-06 | 2019-12-16 | Vertex Pharma | 2-AMINO-6-FLUOR-N- [5-FLUOR-PYRIDIN-3-YL] PYRAZOLO [1,5-A] PYRIMIDIN-3-CARBOXAMIDE COMPOUND USED AS AN AT-KINASE INHIBITOR, DIFFERENTLY DIFFERENTLY DERIVATIVES THEREOF |
PT3137622T (en) | 2014-04-29 | 2022-03-08 | Cytokinetics Inc | Methods of reducing decline in vital capacity |
BR112016028273B1 (en) | 2014-06-05 | 2022-06-28 | Vertex Pharmaceuticals Incorporated | FORMULA I-A COMPOUND, SOLID FORM OF A FORMULA I-1 COMPOUND AND ITS PREPARATION PROCESS |
DK3157566T3 (en) | 2014-06-17 | 2019-07-22 | Vertex Pharma | METHOD OF TREATING CANCER USING A COMBINATION CHK1 AND ATR INHIBITORS |
CN106687115B (en) | 2014-09-09 | 2019-07-19 | 安斯泰来制药有限公司 | The pharmaceutical composition of prevention and/or the treatment urinary incontinence |
JP2018516254A (en) | 2015-05-29 | 2018-06-21 | ファイザー・インク | Novel heterocyclic compounds as inhibitors of vanin 1 enzyme |
EP3355926A4 (en) | 2015-09-30 | 2019-08-21 | Vertex Pharmaceuticals Inc. | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
ES2913423T3 (en) | 2016-02-12 | 2022-06-02 | Cytokinetics Inc | Tetrahydroisoquinoline derivatives |
JP2019524716A (en) | 2016-07-14 | 2019-09-05 | ファイザー・インク | Novel pyrimidinecarboxamides as inhibitors of vanin 1 enzyme |
AU2020311940A1 (en) | 2019-07-11 | 2022-02-03 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070173465A9 (en) * | 1995-10-11 | 2007-07-26 | Monahan Sean D | Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene |
ATE438414T1 (en) * | 2000-06-01 | 2009-08-15 | Univ North Carolina | METHOD AND COMPOSITIONS FOR THE CONTROLLED DELIVERY OF RECOMBINANT PARVOVIRUS VECTORS |
CN1283793C (en) * | 2002-06-03 | 2006-11-08 | 北京大学 | Chemokine-like factor superfamily having skeletal muscle stimulating activity and immunoregulation function |
EP1651638A1 (en) * | 2003-08-08 | 2006-05-03 | Janssen Pharmaceutica N.V. | Pyridyl piperazinyl ureas |
US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
PT2583970E (en) * | 2006-08-02 | 2016-02-08 | Cytokinetics Inc | Certain chemical entities, compositions and methods comprising imidazopyrimidines |
US8299248B2 (en) * | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
CA2696321A1 (en) * | 2007-08-15 | 2009-02-19 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
NL2001694C2 (en) * | 2008-06-18 | 2009-12-22 | Nasophlex B V | Ear stimulator for producing a stimulation signal to an ear. |
AR081331A1 (en) * | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME |
AR081626A1 (en) * | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS |
-
2013
- 2013-04-01 JP JP2015503681A patent/JP6345645B2/en active Active
- 2013-04-01 US US14/389,805 patent/US20150065525A1/en not_active Abandoned
- 2013-04-01 EP EP13773086.7A patent/EP2834269A4/en not_active Withdrawn
- 2013-04-01 SG SG10201701101YA patent/SG10201701101YA/en unknown
- 2013-04-01 EA EA201491605A patent/EA031183B1/en not_active IP Right Cessation
- 2013-04-01 CA CA2868507A patent/CA2868507A1/en not_active Abandoned
- 2013-04-01 WO PCT/US2013/034824 patent/WO2013151938A1/en active Application Filing
- 2013-04-01 KR KR1020147027435A patent/KR20160046693A/en active IP Right Grant
- 2013-04-01 SG SG11201406270YA patent/SG11201406270YA/en unknown
- 2013-04-01 AU AU2013243671A patent/AU2013243671B2/en active Active
- 2013-04-01 CN CN201810509450.1A patent/CN108553467A/en active Pending
- 2013-04-01 MX MX2014011881A patent/MX354965B/en active IP Right Grant
- 2013-04-01 BR BR112014024552A patent/BR112014024552A2/en not_active Application Discontinuation
- 2013-04-01 CN CN201380018757.7A patent/CN104379597A/en active Pending
-
2014
- 2014-09-29 IL IL234885A patent/IL234885A0/en unknown
- 2014-10-01 PH PH12014502217A patent/PH12014502217A1/en unknown
-
2015
- 2015-07-21 HK HK15106936.7A patent/HK1206364A1/en unknown
-
2017
- 2017-02-27 US US15/444,063 patent/US20170266192A1/en not_active Abandoned
- 2017-12-07 AU AU2017272286A patent/AU2017272286B2/en active Active
-
2018
- 2018-05-23 JP JP2018098858A patent/JP2018131460A/en not_active Ceased
-
2019
- 2019-07-05 IL IL267876A patent/IL267876B/en active IP Right Grant
-
2020
- 2020-06-17 JP JP2020104620A patent/JP2020147607A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20160046693A (en) | 2016-04-29 |
SG11201406270YA (en) | 2014-10-30 |
US20170266192A1 (en) | 2017-09-21 |
EP2834269A4 (en) | 2015-12-30 |
EP2834269A1 (en) | 2015-02-11 |
HK1206364A1 (en) | 2016-01-08 |
IL267876A (en) | 2019-09-26 |
AU2013243671B2 (en) | 2017-09-21 |
US20150065525A1 (en) | 2015-03-05 |
EA031183B1 (en) | 2018-11-30 |
BR112014024552A2 (en) | 2017-09-19 |
AU2017272286B2 (en) | 2019-05-09 |
EA201491605A1 (en) | 2015-03-31 |
JP2020147607A (en) | 2020-09-17 |
AU2013243671A1 (en) | 2014-10-16 |
JP2018131460A (en) | 2018-08-23 |
PH12014502217A1 (en) | 2015-01-12 |
WO2013151938A1 (en) | 2013-10-10 |
IL234885A0 (en) | 2014-12-31 |
AU2017272286A1 (en) | 2018-01-04 |
JP6345645B2 (en) | 2018-06-20 |
CN108553467A (en) | 2018-09-21 |
CA2868507A1 (en) | 2013-10-10 |
MX354965B (en) | 2018-03-27 |
CN104379597A (en) | 2015-02-25 |
MX2014011881A (en) | 2016-07-20 |
IL267876B (en) | 2021-03-25 |
JP2015516957A (en) | 2015-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267876B (en) | Compositions for improving diaphragm function | |
HK1250690A1 (en) | Methods | |
HK1208363A1 (en) | New methods | |
EP2836211A4 (en) | Novel methods | |
EP2891325A4 (en) | Acoustic optimization | |
GB201214565D0 (en) | Membrane | |
GB201304182D0 (en) | No details | |
GB201403961D0 (en) | No details | |
GB201218933D0 (en) | An entity | |
HK1180931A1 (en) | An electro-pulsograph | |
EP2905513A4 (en) | Diaphragm damper | |
GB201411220D0 (en) | No details | |
GB2507760B (en) | Methods | |
GB2532391B (en) | Diaphragm | |
GB201208874D0 (en) | Methods | |
EP2705283A4 (en) | Diaphragm | |
GB201313844D0 (en) | No details | |
GB201204280D0 (en) | Methods | |
GB201205792D0 (en) | Loudspeaker | |
GB201403415D0 (en) | No details | |
HK1212895A1 (en) | Saquinavir-no for immunomodulation -no | |
GB201208756D0 (en) | Methods | |
GB201220686D0 (en) | Methods | |
AP2012000550S (en) | E-horn methods | |
GB201216074D0 (en) | Methods |